Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study

INTRODUCTION: In the SPIRIT-H2H (ClinicalTrials.gov: NCT03151551) trial in biologic-naïve patients with active psoriatic arthritis (PsA), ixekizumab (IXE) was superior to adalimumab (ADA) at week 24 in terms of achieving a combined endpoint of ≥ 50% improved response in the American College of Rheum...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S., Sebba, Anthony, Ruderman, Eric M., Schulze-Koops, Hendrik, Sapin, Christophe, Gellett, Amanda M., Sprabery, Aubrey Trevelin, Li, Lingnan, de la Torre, Inmaculada, Gallo, Gaia, Liu-Leage, Soyi, Pillai, Sreekumar, Reis, Paulo, Nash, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695764/
https://www.ncbi.nlm.nih.gov/pubmed/33200394
http://dx.doi.org/10.1007/s40744-020-00250-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695764/
https://www.ncbi.nlm.nih.gov/pubmed/33200394
http://dx.doi.org/10.1007/s40744-020-00250-3

Ejemplares similares